Chlamydia pneumoniae IgG titres and coronary heart disease: Prospective study and meta-analysis

BMJ

Volumn 321, Issue 7255, 2000, Pages 208-213

  Danesh, John ^a   Whincup, Peter ^b   Walker, Mary ^c   Lennon, Lucy ^c   Thomson, Andrew ^c   Appleby, Paul ^d   Wong, Yuk Ki ^e   Bernardes Silva, Martine ^e   Ward, Michael ^e   West, Robert ^f  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^f CARDIFF UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

HOMOCYSTEINE; IMMUNOGLOBULIN G ANTIBODY; LIPID;

ADULT; AMINO ACID BLOOD LEVEL; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CASE CONTROL STUDY; CHLAMYDOPHILA PNEUMONIAE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH CERTIFICATE; GENERAL PRACTICE; HUMAN; ISCHEMIC HEART DISEASE; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; META ANALYSIS; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; SOCIAL STATUS;

ADULT; ANTIBODIES, BACTERIAL; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; CORONARY DISEASE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS;

EID: 0034702531     PISSN: 09598138     EISSN: 14685833     Source Type: Journal    
DOI: 10.1136/bmj.321.7255.208     Document Type: Article

References (30)

1. Saikku P, Leionen M, Mattila K, Ekman MR, Nieminen MS, Makele PH, et al. Serological evidence of an association of a novel chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983–986
2. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350: 430–436
3. Danesh J, Appleby P. Persistent infection and vascular disease: a systematic review. Expert Opin Invest Drugs 1998; 7: 691–713
4. Wong YK, Gallagher PJ, Ward ME. Chlamydia pneumoniae and atherosclerosis. Heart 1999; 81: 232–238
5. Whincup P, Danesh J, Walker M, Lennon L, Thomson A, Appleby P, Atherton J. Prospective study of virulent strains of Helicobacter pylori and coronary heart disease. Circulation 2000; 101: 1647–1652
6. Wong Y-K, Sueur JM, Fall CHD, Orfila J, Ward ME. The species specificity of the microimmunofluorescence antibody test and comparisons with a time resolved fluoroscopic immunoassay for measuring antibodies against Chlamydia pneumoniae. J Clin Pathol 1999; 2: 99–103
7. Wald NJ, Law MR, Morris JK, Zhou X, Wong Y, Ward ME. Chlamydia pneumoniae infection and mortality from ischaemic heart disease: results from a large prospective study. BMJ 2000; 321: 204–207
8. Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction. Circulation 1999; 99: 1161–1164
9. Strachan DP, Carrington D, Mendall MA, Ballam L, Morris J, Butland BK, et al. Relation of Chlamydia pneumoniae serology to mortality and incidence of ischaemic heart disease over 13 years in the Caerphilly prospective heart disease study. BMJ 1999; 318: 1035–1040
10. Tavendale R, Parratt D, Brook RA, Tunstall-Pedoe H. Antibodies to Chlamydia pneumoniae do not predict subsequent CHD in the Scottish Heart Health and MONICA studies [Abstract No P2221]. Eur Heart J 1999; 20(suppl):450
11. Nieto FJ, Folsom A, Sorlie P, Grayston JT, Wang S, Chambless LE. Chlamydia pneumoniae infection and incident coronary heart disease: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 1999; 150: 149–156
12. Ridker PM, Hennekens CH, Buring JE, Kundsin RB, Shih J. Baseline IgG antibody titers to Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk of future cardiovascular disease in women. Ann Intern Med 1999; 131: 573–577
13. Miettinen H, Lehto S, Saikku P, Haffner SM, Rannemaa T, Pyorala K, et al. Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland. Eur Heart J 1996; 17: 682–688
14. Haider AW, Wilson PWF, Larson MG, Sutherland P, Evans JC, O'Donnell CJ, et al. Chlamydia, H pylori and cytomegalovirus seropositivity and risk of cardiovascular disease: the Framingham heart study. J Am Coll Cardiol 1999; 33(suppl A):314A
15. Saikku P, Leinonen M, Tenkanen L, Linnanmaki E, Ekman MR, Manninen V, et al. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki heart study. Ann Intern Med 1992; 116: 273–278
16. Siscovik DS, Schwartz SM, Grayston T, Tracy R, Kuller LH, Krommal RA. Antibody to Chlamydia pneumoniae, herpes simplex virus type 1, cytomegalovirus and incident myocardial infarction and coronary heart disease death: the cardiovascular health study. Circulation 1997; 97(suppl 1):814
17. Glader CA, Boman J, Saikku P, Stenlund H, Weinehall L, Hallmanns, et al. The proatherogenic properties of lipoprotein(a) may be enhanced through the formation of circulating immune complexes containing Chlamydia pneumoniae-specific IgG antibodies. Eur Heart J 2000; 21: 639–646
18. Von Hertzen L, Isoaho R, Kivela SL, Saikku P. Relation of C pneumoniae antibodies to ischaemic heart disease. BMJ 1999; 1575(6).
19. Ossewaarde JM, Feskens EJ, De Vries A, Vallinge CE, Kromhout D. Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacter pylori and cytomegalovirus are not. Epidemiol Infect 1998; 120: 93–99
20. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997; 96: 404–407
21. Roivainen M, Viik-Kajander M, Palosuo T, Toivanen P, Leinonen M, Saikku P, et al. Infections, inflammation and the risk of coronary heart disease. Circulation 2000; 101: 252–258
22. Danesh J, Youngman L, Clark S, Parish S, Peto R, Collins R. Helicobacter pylori infection and early onset myocardial infarction: case-control and sibling pairs study. BMJ 1999; 319: 1157–1162
23. Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: the final report of the ROXIS study. Eur Heart J 1999; 20: 121–127
24. Gurfinkel E, Bozovich G, Daroca A, Beck A, Mautner B. Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS pilot study. Lancet 1997; 350: 404–407
25. Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, et al. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: the azithromycin in coronary artery disease: elimination of myocardial infection with chlamydia (ACADEMIC) study. Circulation 1999; 99: 1540–1547
26. Rothman KJ. Modern epidemiology. Boston: Little Brown, 1986.
27. Chalmers I, Newcombe R, West RR, et al. Adjusted perinatal mortality rates in administrative areas of England and Wales. Health Trends 1978; 10: 24–29
28. West RR. Perinatal and infant mortality in Wales: recent trends, interdistrict variations and associations with socio-environmental characteristics. Int J Epidemiol 1988; 17: 392–396
29. Hart PD, Wright GP. Tuberculosis and social conditions in England. London: National Association for the Prevention of Tuberculosis, 1939.
30. Barker DJP, Osmond C, Winter PD, Margetts B, Simmonds SJ. Weight in infancy and death from ischaemic heart disease. Lancet 1989; 2: 577–580